Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas

Journal of Clinical Pathology

Volumn 64, Issue 8, 2011, Pages 689-694

  Carneiro, Ana ^a   Bendahl, Pär Ola ^a   Åkerman, Måns ^a   Domanski, Henryk A ^a   Rydholm, Anders ^a   Engellau, Jacob ^a   Nilbert, Mef ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EZRIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CYTOSKELETAL PROTEINS; EXTREMITIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; THORAX; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79960730612     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2011.089805     Document Type: Article

References (53)

1. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004;15:1667-72. (Pubitemid 39562608)
2. Weiss S, Glodblum J. Enzinger & Weiss's Soft Tissue Tumors. 4th edn. Philadelphia: Mosby Elsevier, 2001.
3. Curto M, McClatchey AI. Ezrin.a metastatic detERMinant? Cancer Cell 2004;5:113-14.
4. Hunter K. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10:201-4. (Pubitemid 38581790)
5. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-81. (Pubitemid 38524888)
6. Bruce B, Khanna G, Ren L, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007;24:69-78. (Pubitemid 46669242)
7. Algrain M, Turunen O, Vaheri A, et al. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol 1993;120:129-39.
8. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002;3:586-99.
9. Andreoli C, Martin M, Le Borgne R, et al. Ezrin has properties to self-associate at the plasma membrane. J Cell Sci 1994;107:2509-21. (Pubitemid 24292499)
10. Gary R, Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell 1995;6:1061-75.
11. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell 2000;92:305-16.
12. Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46:165-86. (Pubitemid 36452345)
13. Gautreau A, Poullet P, Louvard D, et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96:7300-5. (Pubitemid 29299656)
14. Jensen PV, Larsson LI. Actin microdomains on endothelial cells: association with CD44, ERM proteins, and signaling molecules during quiescence and wound healing. Histochem Cell Biol 2004;121:361-9. (Pubitemid 38756932)
15. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6. (Pubitemid 38524889)
16. Kim C, Shin E, Hong S, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 2009;41:138-44.
17. Kobel M, Langhammer T, Huttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 2006;19:581-7.
18. Ohtani K, Sakamoto H, Rutherford T, et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002;179:79-86. (Pubitemid 34195656)
19. Li Q, Wu M, Wang H, et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 2008;261:55-63.
20. Elzagheid A, Korkeila E, Bendardaf R, et al. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 2008;39:1737-43.
21. Ilmonen S, Vaheri A, Asko-Seljavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol 2005;18:503-10. (Pubitemid 40478113)
22. Makitie T, Carpen O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 2001;42:2442-9. (Pubitemid 32954846)
23. Geiger KD, Stoldt P, Schlote W, et al. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. The American Journal of Pathology 2000;157:1785-93.
24. Weng WH. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005;11:6198-204.
25. Huang HY, Li CF, Fang FM, et al. Prognostic implication of ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol 2010;17:3212-19.
26. ten Heuvel SE, Hoekstra HJ, Bastiaannet E, et al. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression. Appl Immunohistochem Mol Morphol 2009;17:189-95.
27. Fletcher C, Unni K, Mertens F. Pathology and Genetics of tumors of soft tissue and bone. Lyon: IARC, 2002.
28. Engellau J, Samuelsson V, Anderson H, et al. Identification of low-risk tumours in histological high-grade soft tissue sarcomas. Eur J Cancer 2007;43:1927-34. (Pubitemid 47284864)
29. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980:106-20. (Pubitemid 11217753)
30. Migliaccio I, Wu MF, Gutierrez C, et al. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat 2010;123:651-60.
31. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod pathol 1998;11:155-68. (Pubitemid 28144151)
32. Gustafson P, Akerman M, Alvegard TA, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer 2003;39:1568-76. (Pubitemid 36829197)
33. Brambilla D, Fais S. The Janus-faced role of ezrin in "linking" cells to either normal or metastatic phenotype. Int J Cancer 2009;125:2239-45.
34. Meng Y, Lu Z, Yu S, et al. Ezrin promotes invasion and metastasis of pancreatic cancer cells. J Transl Med 2010;8:61.
35. Kim MS, Cho WH, Song WS, et al. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res 2007;27:1171-8.
36. Brennan MF. Local recurrence in soft tissue sarcoma: more about the tumor, less about the surgeon. Ann Surg Oncol 2006;14:528-9.
37. Gronchi A, Miceli R, Fiore M, et al. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol 2007;14:1583-90. (Pubitemid 46791007)
38. Sorbye SW, Kilvaer T, Valkov A, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011;6:e14611.
39. Carneiro A, Bendahl PO, Engellau J, et al. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer 2011;117(6):1279-87.
40. Engellau J, Bendahl PO, Persson A, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol 2005;36:994-1002. (Pubitemid 41253386)
41. Machado I, Navarro S, Giner F, et al. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors. Virchows Arch 2010;457:87-9.
42. Soderstrom M, Palokangas T, Vahlberg T, et al. Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas. APMIS 2010;118:769-76.
43. Wang YF, Shen JN, Xie XB, et al. Expression change of ezrin as a prognostic factor in primary osteosarcoma. Med Oncol. Published Online First: 22 September 2010. doi:10.1007/s12032-010-9684-z.
44. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-62. (Pubitemid 27020593)
45. Rydholm A, Gustafson P. Should tumor depth be included in prognostication of soft tissue sarcoma? BMC Cancer 2003;3:17.
46. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37-42. (Pubitemid 14223231)
47. van Unnik JA, Coindre JM, Contesso C, et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1993;29A:2089-93. (Pubitemid 23348121)
48. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010;11:276-87.
49. Krishnan K, Bruce B, Hewitt S, et al. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006;23:227-36. (Pubitemid 44673812)
50. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-11. (Pubitemid 40490152)
51. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009;8:118.
52. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas. J Clin Oncol 2009;27:3133-40.
53. Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 2011;29:481-8.